Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aitb (AITB)

Aitb (AITB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 55,444
  • Shares Outstanding, K 10,581
  • Annual Sales, $ 7,720 K
  • Annual Income, $ -6,560 K
  • 60-Month Beta -0.26
  • Price/Sales 7.01
  • Price/Cash Flow N/A
  • Price/Book 11.45
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.85
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 06/25/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.22
  • Number of Estimates 1
  • High Estimate -0.22
  • Low Estimate -0.22
  • Prior Year -0.36
  • Growth Rate Est. (year over year) +38.89%

Price Performance

See More
Period Period Low Period High Performance

Most Recent Stories

More News
CORRECTING and REPLACING - AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

Announces name change to

AITB : 4.6500 (-6.44%)
AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

Announces name change to

AITB : 4.6500 (-6.44%)
AIT Therapeutics Announces Study Published in Journal of Cystic Fibrosis

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 4.6500 (-6.44%)
AIT Therapeutics Presents Data at the 2019 American Thoracic Society Conference in Dallas, TX

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 4.6500 (-6.44%)
AIT Therapeutics Announces Oral and Poster Presentations at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions,...

AITB : 4.6500 (-6.44%)
AIT Therapeutics to Present Data at the 2019 American Thoracic Society Conference in Dallas, TX

AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 4.6500 (-6.44%)
AIT Therapeutics Announces Uplisting to the Nasdaq Capital Market

AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 4.6500 (-6.44%)
AIT Therapeutics to Demonstrate NO Generator and Delivery System at Pediatric Academic Societies Meeting in Baltimore, MD on April 27-30

AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions...

AITB : 4.6500 (-6.44%)
Recro Pharma Falls as FDA Denies Approval to Pain Candidate

FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

ALKS : 19.77 (-2.32%)
OCUL : 5.14 (-9.03%)
REPH : 15.61 (-7.49%)
AITB : 4.6500 (-6.44%)
Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

PFE : 34.67 (-2.94%)
AERI : 20.30 (-5.97%)
AITB : 4.6500 (-6.44%)
ASRT : 1.17 (-10.69%)
Trade AITB with:

Key Turning Points

2nd Resistance Point 5.0767
1st Resistance Point 4.8633
Last Price 4.6500
1st Support Level 4.5433
2nd Support Level 4.4367

See More

52-Week High 4.9700
Fibonacci 61.8% 4.8478
Fibonacci 50% 4.8100
Fibonacci 38.2% 4.7722
Last Price 4.6500
52-Week Low 4.6500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar